A newly created investment firm is offering an investment product that allows individuals to select a portfolio of pharmaceutical and biotech companies working on treatments to fill major illnesses. WellSpring BioCapital Partners, based in Philadelphia, has identified Alzheimer's disease, breast and ovarian cancer, diabetes, prostate cancer and rheumatoid arthritis as the bases of the portfolios it will offer, with each ailment portfolio identifying companies working on treatments.

Related Summaries